Today: 16 June 2026
Browse Category

NASDAQ:RYTM 11 December 2025 - 30 December 2025

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals shares dropped 4.2% to $107.85 in early afternoon trading Tuesday as biotech stocks broadly declined. Investors are awaiting an FDA decision on expanding Imcivree’s label, now expected by March 20, 2026. Board member Camille L. Bedrosian resigned effective immediately, according to an SEC filing. Major biotech ETFs fell over 1% while the broader market was flat.
30 December 2025
··
Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals shares jumped over 15% to a record high near $121 on December 11 after reporting positive interim Phase 2 data for setmelanotide in Prader-Willi syndrome. Six of eight patients showed BMI reductions at three months, and most saw declines in hunger scores. The company plans a Phase 3 trial pending Phase 2 completion. RYTM stock is up around 80–90% year-to-date.
11 December 2025
·

Stock Market Today

  • FTSE 100's Barratt Redrow Down 33%, Offers 5.6% Dividend Yield Amid Market Uncertainty
    June 16, 2026, 3:06 PM EDT. Barratt Redrow, a major UK housebuilder, has seen its shares drop 33% in 2026 but offers a compelling 5.6% dividend yield. Despite economic challenges including inflationary pressures tied to the Iran conflict, the company remains on track with strong forward sales of £3.54 billion and aims to complete up to 17,800 homes this year. CEO David Thomas signals resilience with raised net cash guidance between £550 million and £650 million. RBC Capital rates Barratt and Persimmon as market leaders, assigning a 350p price target-up 38% from current levels-due to a modest 10 P/E ratio forecast for 2026. While housing demand remains supported by chronic shortages, valuation concerns linked to broader market fears persist. Investors face uncertainty over the sector's recovery timing amid dividend yield cuts and ongoing market volatility.

Latest articles

Ford Shares Dip After China Software Rule Adds Fresh Risk

Ford Shares Dip After China Software Rule Adds Fresh Risk

16 June 2026
Ford shares slipped 1.1% to $14.61 after Reuters reported the company needs U.S. approval to keep importing China-built Lincoln Nautilus SUVs due to new connected-vehicle rules, raising fresh regulatory uncertainty for investors ahead of Ford’s expected Q2 earnings report.
MARA Holdings Jumps After Bitcoin Treasury Update Brings Miner Into View

MARA Holdings Jumps After Bitcoin Treasury Update Brings Miner Into View

16 June 2026
MARA Holdings surged 2.1% to $14.94 on heavy volume, outperforming the Nasdaq, as investors focused on speculation about a 1,000-Bitcoin treasury purchase reported by Crypto.news, though MARA has not confirmed the transaction; the stock’s rally comes despite Q1 revenue and net loss declines, with analysts holding a mixed view and price targets averaging $17–$18.38, reflecting high volatility and ongoing execution risks.
Go toTop